Royce & Associates LP Has $108.41 Million Stock Position in Enovis Co. (NYSE:ENOV)

Royce & Associates LP raised its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 2.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,470,576 shares of the company's stock after purchasing an additional 66,891 shares during the quarter. Enovis accounts for 1.0% of Royce & Associates LP's investment portfolio, making the stock its 4th largest position. Royce & Associates LP owned approximately 4.35% of Enovis worth $108,409,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ENOV. State of New Jersey Common Pension Fund D grew its stake in Enovis by 15.4% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 43,404 shares of the company's stock valued at $1,869,000 after buying an additional 5,801 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Enovis by 14.3% in the third quarter. Victory Capital Management Inc. now owns 32,846 shares of the company's stock valued at $1,414,000 after purchasing an additional 4,099 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Enovis by 19.8% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 11,829 shares of the company's stock valued at $509,000 after purchasing an additional 1,953 shares during the period. Natixis Advisors LLC purchased a new stake in Enovis during the 3rd quarter worth about $546,000. Finally, Mutual of America Capital Management LLC boosted its stake in Enovis by 5.6% in the 3rd quarter. Mutual of America Capital Management LLC now owns 30,183 shares of the company's stock worth $1,299,000 after purchasing an additional 1,604 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Enovis Price Performance

Shares of ENOV stock traded down $0.05 during trading on Thursday, hitting $39.38. The company had a trading volume of 568,330 shares, compared to its average volume of 666,684. The stock's 50-day moving average is $42.97 and its two-hundred day moving average is $43.59. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -17.98 and a beta of 2.05. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. As a group, analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reduced their price target on shares of Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research report on Thursday, February 27th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.